Zemplar
Zemplar (paricalcitol) is a synthetically manufactured active vitamin D analog. It acts by reducing parathyroid hormone (PTH) levels, helping to manage calcium and phosphorus levels in patients with chronic kidney disease, thereby preventing bone loss and related metabolic complications.
Dosage by Body Weight
Dosage must be strictly individualized and based on serum parathyroid hormone (iPTH), calcium, and phosphorus levels. Administered orally (either daily or three times a week) or intravenously during hemodialysis. Regular blood monitoring is required.
- Body Weight
- Below 5 kg
- Dose
- Not routinely established
- Frequency
- Consult pediatric nephrologist
- Tracking Notes
- Safety and efficacy in pediatric patients under 5 kg have not been established. Strictly use only under expert specialist guidance.
- Body Weight
- 5-7 kg
- Dose
- Highly individualized based on BSA and baseline iPTH
- Frequency
- Three times weekly or as prescribed
- Tracking Notes
- Requires calculated dosing based on body surface area (BSA) and close monitoring of calcium and phosphorus levels.
- Body Weight
- 8-10 kg
- Dose
- Highly individualized based on BSA and baseline iPTH
- Frequency
- Three times weekly or as prescribed
- Tracking Notes
- Dose adjustments must be made progressively depending on serum iPTH response.
- Body Weight
- 11-15 kg
- Dose
- Highly individualized based on BSA and baseline iPTH
- Frequency
- Three times weekly or as prescribed
- Tracking Notes
- Ensure adequate monitoring to prevent hypercalcemia.
- Body Weight
- 16-20 kg
- Dose
- Highly individualized based on BSA and baseline iPTH
- Frequency
- Three times weekly or as prescribed
- Tracking Notes
- Monitor serum calcium-phosphorus product to avoid calcification risks.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routinely established | Consult pediatric nephrologist | Safety and efficacy in pediatric patients under 5 kg have not been established. Strictly use only under expert specialist guidance. |
| 5-7 kg | Highly individualized based on BSA and baseline iPTH | Three times weekly or as prescribed | Requires calculated dosing based on body surface area (BSA) and close monitoring of calcium and phosphorus levels. |
| 8-10 kg | Highly individualized based on BSA and baseline iPTH | Three times weekly or as prescribed | Dose adjustments must be made progressively depending on serum iPTH response. |
| 11-15 kg | Highly individualized based on BSA and baseline iPTH | Three times weekly or as prescribed | Ensure adequate monitoring to prevent hypercalcemia. |
| 16-20 kg | Highly individualized based on BSA and baseline iPTH | Three times weekly or as prescribed | Monitor serum calcium-phosphorus product to avoid calcification risks. |
Formulation
Purpose
Prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stages 3, 4, and 5.
Generic Name
ParicalcitolScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.